The chondrosarcoma market is gaining traction owing to increasing incidences of bone cancer cases. Chondrosarcoma is a type of bone cancer that starts in the cartilage cells or soft connective tissues. Treatment of chondrosarcoma relies on the stage and grade of the cancer cells and includes chemotherapy, radiation therapy, and surgery.

The chondrosarcoma market is estimated to be valued at USD 961.2 Mn in 2024 and is expected to reach USD 1,521.1 Mn by 2031, growing at a compound annual growth rate (CAGR) of 6.8% from 2024 to 2031.
Advancements in chemotherapy, radiotherapy, and surgical procedures have improved survival rates. However, effective targeted therapies are still not available.
Key Takeaways
Key players: Key players operating in the chondrosarcoma market are Pfizer, Eli Lilly, Bristol-Myers Squibb, Hikma Pharmaceuticals, TEVA Pharmaceuticals, Cipla, Mylan, Accord Healthcare, and Natco Pharma.
Growing demand: Rising prevalence of bone tumors and increasing healthcare expenditure are fueling the growth of the Chondrosarcoma Market. According to a report by Cancer Research UK, around 113 new cases of chondrosarcoma were registered in the UK in 2016.
Technological advancement: Adoption of advanced diagnostic techniques such as CT scan, MRI, and PET scan have enabled early and accurate diagnosis of chondrosarcoma. Further, technological advancement in chemotherapy and surgical procedures have improved treatment outcomes.
Market Trends
Inclined towards targeted therapies: Players are focusing on development of targeted therapies to improve treatment effectiveness with reduced side effects. Ongoing clinical trials are evaluating small molecule inhibitors and immune checkpoint inhibitors.
Combination therapies gaining traction: Combining chemotherapy and radiation or immunotherapy showed promising results in preclinical studies. Biologics in combination with monoclonal antibodies hold potential to become a standard treatment regime.
Market Opportunities
Untapped emerging markets: Asia Pacific and Latin America offer lucrative opportunities for market players owing to growing healthcare infrastructure, large patient population and rising disposable incomes.
Personalized treatment: Advancing knowledge of genetics and biomarkers may lead to development of tailored treatment protocols based on individual patient’s tumor characteristics. This represents an upcoming opportunity.
Impact of COVID-19 on Chondrosarcoma Market Growth
The outbreak of the COVID-19 pandemic has adversely impacted the global chondrosarcoma market. During the initial phase of the pandemic, the focus of healthcare systems worldwide shifted towards managing the COVID infected patients which led to postponement of several non-emergency medical procedures including chondrosarcoma diagnosis and treatment. This translated to a dip in the demand for chondrosarcoma drugs and therapies. Lockdowns and social distancing measures further constrained the patient visits to healthcare facilities. However, with the progressive resumption of healthcare services, the market is regaining lost growth momentum.
Still, the pandemic has brought certain challenges for the market players to address. Supply chain disruptions caused delays in procurement of raw materials as well as finished drugs. Research & development activities faced restrictions due to disruptions in clinical trials. Telehealth and home delivery became more prominent to ensure continuity of care while social distancing is maintained. Market players are also exploring strategic partnerships and collaborations to accelerate product development and elevate service delivery standards to mitigate future healthcare crises.
Geographical Concentration of Chondrosarcoma Market
North America accounts for the largest share of the global chondrosarcoma market in terms of value. This is attribted to rising prevalence of chondrosarcoma cancer cases in the US and Canada coupled with advanced healthcare infrastructure and greater access to advanced treatment options in the region. Additionally, presence of several market leaders, favorable reimbursement policies, and high healthcare expenditure capacity of patients have propelled the regional market growth over the years.
Asia Pacific is identified as the fastest growing market for chondrosarcoma globally. Factors such as increasing healthcare spending, growing public awareness about this rare form of cancer, rising patient population due to sedentary lifestyles will continue to propel the regional market during the forecast period. Moreover, expanding pharmaceutical industry, improving diagnostic capabilities, and focus of global market players on tapping opportunities in emerging Asian countries are also boosting the APAC market trajectory.
Regional Concentration of Chondrosarcoma Market
North America accounts for the largest share of the global chondrosarcoma market in terms of value. This is attribted to rising prevalence of chondrosarcoma cancer cases in the US and Canada coupled with advanced healthcare infrastructure and greater access to advanced treatment options in the region. Additionally, presence of several market leaders, favorable reimbursement policies, and high healthcare expenditure capacity of patients have propelled the regional market growth over the years.
Asia Pacific is identified as the fastest growing market for chondrosarcoma globally. Factors such as increasing healthcare spending, growing public awareness about this rare form of cancer, rising patient population due to sedentary lifestyles will continue to propel the regional market during the forecast period. Moreover, expanding pharmaceutical industry, improving diagnostic capabilities, and focus of global market players on tapping opportunities in emerging Asian countries are also boosting the APAC market trajectory.

Get more insights on- Chondrosarcoma Market

Get this Report in Japanese Language: 軟骨肉腫市場

Get this Report in Korean Language: 연골육종 시장

About Author:

Ravina Pandya, Content Writer, has a strong foothold in the market research industry. She specializes in writing well-researched articles from different industries, including food and beverages, information and technology, healthcare, chemical and materials, etc. (https://www.linkedin.com/in/ravina-pandya-1a3984191)